DailyPharm: 翰林制药 drives 开放式创新… expanding 眼科 partners
Scale of 眼科 drug 技术转让 with RudaCure expands to over KRW 20 billion
Focused investment in 黄斑变性 生物类似药s… partnerships with Altos Bio and others
Stable cash generation capacity connects to external investment… second-generation owner also supports
[DailyPharm = Reporter Lee Seok-joon] 翰林制药 is accelerating its 开放式创新 drive. In particular, it has partnered with multiple companies to expand its core 眼科 business. The scale of 技术转让s with RudaCure has exceeded KRW 20 billion.
The expansion of the 开放式创新 business is underpinned by 翰林制药's strong operating cash generation capability. The company has been achieving an operating profit margin of around 15% for several years. The second-generation owner is also providing support.
翰林制药 recently completed a 技术转让 of RudaCure's 角膜溃疡 and 角膜损伤 treatment candidate (RCI001U). 翰林制药 will hold domestic production and sales rights for RCI001U technology, while RudaCure will receive milestone payments including 临床试验 approvals. The deal is worth KRW 7 billion (including an upfront payment of KRW 1 billion).
